<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ParagraphFour.com | gregoryglass | Activity</title>
	<link>https://paragraphfour.com/members/gregoryglass/activity/</link>
	<atom:link href="https://paragraphfour.com/members/gregoryglass/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for gregoryglass.</description>
	<lastBuildDate>Sat, 13 Jun 2026 13:15:49 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">31193bba9d78e080efa1416f98f9e470</guid>
				<title>gregoryglass updated &#039;Branded Companies Report &#039;: The Paragraph Four Report ®
Branded Companies [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/12017/</link>
				<pubDate>Thu, 11 Jun 2026 16:01:59 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Branded Companies Report</b></p>
<p><b>List of Companies with Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1, 2003)</p>
<p><b>ABBVIE&hellip;</b><span class="activity-read-more" id="activity-read-more-12017"><a href="https://paragraphfour.com/activity/p/12017/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">cdd585cfa55305c8ffb6f08a52f10016</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #2 (F-P) &#039;: The Paragraph Four Report ®
Generic Companies Report #2 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/12016/</link>
				<pubDate>Thu, 11 Jun 2026 16:01:19 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #2 (F-P)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-12016"><a href="https://paragraphfour.com/activity/p/12016/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">4e4a6ed42b2e9cfccfff13a111f71366</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #3 (Q-Z) &#039;: The Paragraph Four Report ®
Generic Companies Report #3 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/12014/</link>
				<pubDate>Thu, 11 Jun 2026 13:31:11 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #3 (Q-Z)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-12014"><a href="https://paragraphfour.com/activity/p/12014/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">0c4c4c45903d4ce46c76e33304e22376</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #1 (A-E) &#039;: The Paragraph Four Report ®
Generic Companies Report #1 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/12011/</link>
				<pubDate>Tue, 09 Jun 2026 21:49:24 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #1 (A-E)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-12011"><a href="https://paragraphfour.com/activity/p/12011/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a2fa85a28ae3ca3bad92ae81c37a45c5</guid>
				<title>gregoryglass updated &#039;Branded Companies Report &#039;: The Paragraph Four Report ®
Branded Companies [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/12010/</link>
				<pubDate>Tue, 09 Jun 2026 21:48:44 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Branded Companies Report</b></p>
<p><b>List of Companies with Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1, 2003)</p>
<p><b>ABBOTT LAB&hellip;</b><span class="activity-read-more" id="activity-read-more-12010"><a href="https://paragraphfour.com/activity/p/12010/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ca3be7865f8dc763c581b59b40cece5e</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #2 (F-P) &#039;: The Paragraph Four Report ®
Generic Companies Report #2 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/12007/</link>
				<pubDate>Tue, 09 Jun 2026 20:46:42 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #2 (F-P)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-12007"><a href="https://paragraphfour.com/activity/p/12007/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">dc6ad2bd0e9a23152e9ee094bfd6a142</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #3 (Q-Z) &#039;: The Paragraph Four Report ®
Generic Companies Report #3 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/12004/</link>
				<pubDate>Tue, 09 Jun 2026 19:51:34 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #3 (Q-Z)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-12004"><a href="https://paragraphfour.com/activity/p/12004/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">cfd3291a0d822bf3f79263ac2715f4ec</guid>
				<title>gregoryglass updated &#039;Branded Companies Report &#039;: The Paragraph Four Report ®
Branded Companies [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/12001/</link>
				<pubDate>Tue, 09 Jun 2026 19:33:36 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Branded Companies Report</b></p>
<p><b>List of Companies with Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1, 2003)</p>
<p><b>ABBOTT LAB&hellip;</b><span class="activity-read-more" id="activity-read-more-12001"><a href="https://paragraphfour.com/activity/p/12001/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">3ffa996bb400fe52913d4d238519ef23</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #1 (A-E) &#039;: The Paragraph Four Report ®
Generic Companies Report #1 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/12000/</link>
				<pubDate>Tue, 09 Jun 2026 19:32:58 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #1 (A-E)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-12000"><a href="https://paragraphfour.com/activity/p/12000/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6f3409f8213b238bf9d98116fcb6b09d</guid>
				<title>gregoryglass updated &#039;Paragraph IV Appellate Judges (Schall &#8211; Wallach) &#039;: The Paragraph Four Report®
The Appellate Judges (Schall - [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11998/</link>
				<pubDate>Tue, 09 Jun 2026 18:56:29 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>The Appellate Judges (Schall &#8211; Wallach)</b></p>
<p>This Section provides data on federal judges who preside in The Federal Circuit Court of Appeals. The Federal Circuit has exclusive appellate jurisdiction over Paragraph IV cases which means that a party that loses in the district court can only appeal the decision to the&hellip;<span class="activity-read-more" id="activity-read-more-11998"><a href="https://paragraphfour.com/activity/p/11998/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">211129415e0305e8765130cd3bde564b</guid>
				<title>gregoryglass updated &#039;Paragraph IV Appellate Judges (Bryson-Hughes) &#039;: The Paragraph Four Report®
The Appellate Judges (Bryson - [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11997/</link>
				<pubDate>Tue, 09 Jun 2026 18:55:59 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>The Appellate Judges (Bryson &#8211; Hughes)</b></p>
<p>This Section provides data on federal judges who preside in The Federal Circuit Court of Appeals. The Federal Circuit has exclusive appellate jurisdiction over Paragraph IV cases which means that a party that loses in the district court can only appeal the decision to the&hellip;<span class="activity-read-more" id="activity-read-more-11997"><a href="https://paragraphfour.com/activity/p/11997/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6dfaec614e39843304a3a6bf95c12460</guid>
				<title>gregoryglass updated &#039;Court of Appeals Decisions &#8211; by Case Name &#039;: The Paragraph Four Report®
Court of Appeals Opinions by [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11996/</link>
				<pubDate>Tue, 09 Jun 2026 18:53:10 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>Court of Appeals Opinions by Case Name</b></p>
<p>Opinions from the Court of Appeals for the Federal Circuit can be found in several places in ParagraphFour.com. Each Opinion issued for a particular product can be found under the product name, and you can also see how each individual Appellate Judge ruled in their various&hellip;<span class="activity-read-more" id="activity-read-more-11996"><a href="https://paragraphfour.com/activity/p/11996/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">c74d83d2280bc01ca2058c386449827e</guid>
				<title>gregoryglass updated &#039;OxyContin®(oxycodone) ER Tabs (NDA 22-272) Part 2 &#039;: OxyContin®(oxycodone) Extended-release Tablet (NDA 22-272) [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11995/</link>
				<pubDate>Tue, 09 Jun 2026 18:50:47 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>OxyContin®(oxycodone) Extended-release Tablet (NDA 22-272) Part 2</b><br />
<b>Company </b> PURDUE<br />
<b>Date of First Filing</b> October 4, 2010 (40mg), October 18, 2010 (30, 60, and 90mg), October 25, 2010 (10mg), October 28, 2010 (15mg), and October 29, 2010 (20mg).</p>
<p><b>Editor&#8217;s Note</b> This Product Topic covers the fifth set of cases filed on this product since 2001.&hellip;<span class="activity-read-more" id="activity-read-more-11995"><a href="https://paragraphfour.com/activity/p/11995/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">43f3bcad6872c5d9643dcc121e7ea5ff</guid>
				<title>gregoryglass updated &#039;Paragraph IV Appellate Judges (Prost &#8211; Reyna) &#039;: The Paragraph Four Report®
The Appellate Judges (Prost - [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11994/</link>
				<pubDate>Mon, 08 Jun 2026 12:31:57 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>The Appellate Judges (Prost &#8211; Reyna)</b></p>
<p>This Section provides data on federal judges who preside in The Federal Circuit Court of Appeals. The Federal Circuit has exclusive appellate jurisdiction over Paragraph IV cases which means that a party that loses in the district court can only appeal the decision to the Federal&hellip;<span class="activity-read-more" id="activity-read-more-11994"><a href="https://paragraphfour.com/activity/p/11994/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">7095b8870868b5d6079a5597285f486d</guid>
				<title>gregoryglass updated &#039;Paragraph IV Appellate Judges (Bryson-Hughes) &#039;: The Paragraph Four Report®
The Appellate Judges (Bryson - [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11993/</link>
				<pubDate>Mon, 08 Jun 2026 12:30:50 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>The Appellate Judges (Bryson &#8211; Hughes)</b></p>
<p>This Section provides data on federal judges who preside in The Federal Circuit Court of Appeals. The Federal Circuit has exclusive appellate jurisdiction over Paragraph IV cases which means that a party that loses in the district court can only appeal the decision to the&hellip;<span class="activity-read-more" id="activity-read-more-11993"><a href="https://paragraphfour.com/activity/p/11993/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">2cab1e033cd04ab6fff1a6929efd7e46</guid>
				<title>gregoryglass updated &#039;Court of Appeals Decisions &#8211; by Case Name &#039;: The Paragraph Four Report®
Court of Appeals Opinions by [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11992/</link>
				<pubDate>Mon, 08 Jun 2026 12:28:32 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>Court of Appeals Opinions by Case Name</b></p>
<p>Opinions from the Court of Appeals for the Federal Circuit can be found in several places in ParagraphFour.com. Each Opinion issued for a particular product can be found under the product name, and you can also see how each individual Appellate Judge ruled in their various&hellip;<span class="activity-read-more" id="activity-read-more-11992"><a href="https://paragraphfour.com/activity/p/11992/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">1fc7c2d602cdd3fca8473423c06d49c0</guid>
				<title>gregoryglass updated &#039;Last Month&#8217;s Paragraph IV Highlights &#039;: May 2026</title>
				<link>https://paragraphfour.com/activity/p/11989/</link>
				<pubDate>Sun, 31 May 2026 11:58:31 -0400</pubDate>

									<content:encoded><![CDATA[<p>May 2026</p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">eb2fae9962217b9889f8e33e818a8805</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #1 (A-E) &#039;: The Paragraph Four Report ®
Generic Companies Report #1 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11986/</link>
				<pubDate>Sat, 30 May 2026 20:20:31 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #1 (A-E)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11986"><a href="https://paragraphfour.com/activity/p/11986/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f585db10ef52b811c28d3bd3d6517913</guid>
				<title>gregoryglass updated &#039;Inlyta®(axitinib) Tablets &#039;: Inlyta®(axitinib) Tablets
Company  PFIZER
Date of First [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11985/</link>
				<pubDate>Sat, 30 May 2026 20:19:21 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Inlyta®(axitinib) Tablets</b><br />
<b>Company </b> PFIZER<br />
<b>Date of First Filing</b> February 23, 2018</p>
<p><b>Paragraph IV Applicant:</b> Apotex<br />
<b>Case Name: </b> PFIZER INC et al v. APOTEX INC et al<br />
<b>Court/Case #: </b> Delaware District Court (dedc) 1:2018cv00795<br />
<b>Date Filed:</b> 5/25/18<br />
<b>Judge: </b> Andrews<br />
<b>Product Strength:</b> 1 mg and 5 mg<br />
<b>Litigated Patents (expiration): </b> 8,791,140&hellip;<span class="activity-read-more" id="activity-read-more-11985"><a href="https://paragraphfour.com/activity/p/11985/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">eb672c9b43f9e5492334a93e3be56540</guid>
				<title>gregoryglass updated &#039;Representation List (Branded) &#039;: The Paragraph Four Report®
Representation List (Branded [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11984/</link>
				<pubDate>Sat, 30 May 2026 20:05:50 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>Representation List (Branded Companies)</b></p>
<p>In March 2019, we reconstructed this section. The original section covered all law firms representing brand companies in PIV cases filed since 2003. The original list of branded companies with represented law firms is in this pdf file, if you need it for reference:<br />
<a href="https://paragraphfour.com/uploads/educ/Representation List Brand Legacy.pdf" rel="nofollow ugc"><img loading="lazy" src="https://paragraphfour.com/html/mime_types/pdf.gif" /> Legacy&hellip;</a><span class="activity-read-more" id="activity-read-more-11984"><a href="https://paragraphfour.com/activity/p/11984/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">9c36ae98e03e66835d7a7c695d9a197a</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #2 (F-P) &#039;: The Paragraph Four Report ®
Generic Companies Report #2 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11983/</link>
				<pubDate>Sat, 30 May 2026 20:03:00 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #2 (F-P)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11983"><a href="https://paragraphfour.com/activity/p/11983/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">caa04be7cb7675861b6c9a8f17f12355</guid>
				<title>gregoryglass updated &#039;Eliquis®(apixaban) Tablets &#039;: Eliquis®(apixaban) Tablets
Company  BRISTOL-MYERS 
Date of [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11976/</link>
				<pubDate>Sat, 30 May 2026 18:55:52 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Eliquis®(apixaban) Tablets</b><br />
<b>Company </b> BRISTOL-MYERS<br />
<b>Date of First Filing</b> December 28, 2016</p>
<p><b>Special Note 1:</b> On 4/5/17, Bristol-Myers filed PIV cases against 9 ANDA filers and on 4/10/17, PIV cases against 15 ANDA filers. All of these 24 cases were filed in Delaware and involve the 2.5mg and 5mg strengths. Please also see Special Note 2 below&hellip;<span class="activity-read-more" id="activity-read-more-11976"><a href="https://paragraphfour.com/activity/p/11976/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">47316e27b871e5b52b0b88342f2ab6b3</guid>
				<title>gregoryglass updated &#039;Belrapzo®(bendamustine) Injection &#039;: Belrapzo®(bendamustine) Injection
Company  EAGLE
Date of [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11973/</link>
				<pubDate>Sat, 30 May 2026 18:43:05 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Belrapzo®(bendamustine) Injection</b><br />
<b>Company </b> EAGLE<br />
<b>Date of First Filing</b> Not applicable/reported by FDA</p>
<p><b>Paragraph IV Applicant:</b> Slayback<br />
<b>Case Name: </b> EAGLE PHARMACEUICALS INC v. SLAYBACK PHARMA LLC<br />
<b>Court/Case #: </b> Court of Appeals for the Federal Circuit (cafc) 19-1924<br />
<b>Date Filed:</b> 5/24/19<br />
<b>Judge: </b> O&#8217;Malley, Reyna, Chen<br />
<b>Product Strength:</b>&hellip;<span class="activity-read-more" id="activity-read-more-11973"><a href="https://paragraphfour.com/activity/p/11973/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">bddb5e5caf8762908aef71a9b6ebb1ac</guid>
				<title>gregoryglass updated &#039;Injectafer®(ferric carboxymaltose) Injection &#039;: Injectafer®(ferric carboxymaltose) Injection 
Company  VIFOR [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11966/</link>
				<pubDate>Sat, 30 May 2026 13:30:29 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Injectafer®(ferric carboxymaltose) Injection </b><br />
<b>Company </b> VIFOR INTERNATIONAL<br />
<b>Date of First Filing</b> March 27, 2019 and February 22, 2024 (50 mg/10 mL)</p>
<p><b>Paragraph IV Applicant:</b> Mylan<br />
<b>Case Name: </b> VIFOR (INTERNATIONAL) AG et al v. MYLAN LABORATORIES LTD<br />
<b>Court/Case #: </b> New Jersey District Court (njdc) 3:2019cv13955<br />
<b>Date Filed:</b> 6/18/19<br />
<b>Judge: </b> Wolfs&hellip;<span class="activity-read-more" id="activity-read-more-11966"><a href="https://paragraphfour.com/activity/p/11966/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">581f856b0622ef56a5d2e672b5fdd469</guid>
				<title>gregoryglass updated &#039;Myrbetriq®(mirabegron) Extended-release Tablets &#039;: Myrbetriq®(mirabegron) Extended-release Tablets
Annual [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11951/</link>
				<pubDate>Thu, 28 May 2026 17:30:42 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Myrbetriq®(mirabegron) Extended-release Tablets</b><br />
<b>Annual Sales </b><br />
<b>Company </b> ASTELLAS<br />
<b>Date of First Filing</b> June 28, 2016</p>
<p><b>Special Summary Note #1:</b> In 2016, Astellas brought PIV actions against 9 ANDA filers as listed below. By October 2020, all of the parties settled these original cases. On 11/24/20, the USPTO issued a new patent (10,842,780,&hellip;<span class="activity-read-more" id="activity-read-more-11951"><a href="https://paragraphfour.com/activity/p/11951/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">972ea2503eeeb1b5e0b2cf5a1c5631e9</guid>
				<title>gregoryglass updated &#039;Kyprolis®(carfilzomib) For Injection &#039;: Kyprolis®(carfilzomib) For Injection
Annual Sales: [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11948/</link>
				<pubDate>Wed, 27 May 2026 20:57:43 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Kyprolis®(carfilzomib) For Injection</b><br />
<b>Annual Sales:</b> $948M<br />
<b>Company </b> ONYX THERPEUTICS<br />
<b>Date of First Filing</b> July 20, 2016 and October 5, 2017 (30mg/vial) and November 28, 2018 (10mg/vial)</p>
<p><b>Paragraph IV Applicant:</b> Cipla<br />
<b>Case Name: </b> ONYX THERAPEUTICS INC v. CIPLA LIMITED et al<br />
<b>Court/Case #: </b> Court of Appeals for the Federal Circuit (cafc)&hellip;<span class="activity-read-more" id="activity-read-more-11948"><a href="https://paragraphfour.com/activity/p/11948/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ef5efaf38c3f129bfddefeeec2b87181</guid>
				<title>gregoryglass updated &#039;Invega Sustenna®(paliperidone) ER Inj Suspension &#039;: Invega Sustenna®(paliperidone) Extended-release Injectable [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11946/</link>
				<pubDate>Wed, 27 May 2026 20:46:00 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Invega Sustenna®(paliperidone) Extended-release Injectable Suspension</b><br />
<b>Annual Sales </b> $3.1B (product family)<br />
<b>Company </b> JANSSEN<br />
<b>Date of First Filing</b> November 21, 2017</p>
<p><b>Paragraph IV Applicant:</b> Teva<br />
<b>Case Name: </b> JANSSEN PHARMACEUTICALS INC et al v. TEVA PHARMACEUTICALS USA INC et al<br />
<b>Court/Case #: </b> Court of Appeals for the Federal Circuit (cafc)&hellip;<span class="activity-read-more" id="activity-read-more-11946"><a href="https://paragraphfour.com/activity/p/11946/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">672f039b64d9faea46b5884e91c6f1c3</guid>
				<title>gregoryglass updated &#039;Xarelto®(rivaroxaban) Tablets &#039;: Xarelto®(rivaroxaban) Tablets
Annual Sales  $2.36B (as [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11942/</link>
				<pubDate>Tue, 26 May 2026 15:09:29 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Xarelto®(rivaroxaban) Tablets</b><br />
<b>Annual Sales </b> $2.36B (as reported by J&amp;J)<br />
<b>Company </b> BAYER (JANSSEN)<br />
<b>Date of First Filing</b> July 1, 2015 and November 15, 2018 (2.5mg)</p>
<p><b>Special Note 1:</b> On 10/9/15, Bayer filed its PIV case against 7 ANDA filers (Aurobindo through Torrent). Bayer included all three patents against all of the defendants except where&hellip;<span class="activity-read-more" id="activity-read-more-11942"><a href="https://paragraphfour.com/activity/p/11942/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ae79b48879b3971fc94fce2be3e7f9c3</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #3 (Q-Z) &#039;: The Paragraph Four Report ®
Generic Companies Report #3 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11941/</link>
				<pubDate>Fri, 22 May 2026 19:26:22 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #3 (Q-Z)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11941"><a href="https://paragraphfour.com/activity/p/11941/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">be542a287e0bfb473ed9a8a1135cf81b</guid>
				<title>gregoryglass updated &#039;Branded Companies Report &#039;: The Paragraph Four Report ®
Branded Companies [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11940/</link>
				<pubDate>Fri, 22 May 2026 19:25:39 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Branded Companies Report</b></p>
<p><b>List of Companies with Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1, 2003)</p>
<p><b>ABBOTT LAB&hellip;</b><span class="activity-read-more" id="activity-read-more-11940"><a href="https://paragraphfour.com/activity/p/11940/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">338e087e8b606af0a7b490c732a5440e</guid>
				<title>gregoryglass updated &#039;Paragraph IV Appellate Judges (Bryson-Hughes) &#039;: The Paragraph Four Report®
The Appellate Judges (Bryson - [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11938/</link>
				<pubDate>Fri, 22 May 2026 19:01:42 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>The Appellate Judges (Bryson &#8211; Hughes)</b></p>
<p>This Section provides data on federal judges who preside in The Federal Circuit Court of Appeals. The Federal Circuit has exclusive appellate jurisdiction over Paragraph IV cases which means that a party that loses in the district court can only appeal the decision to the&hellip;<span class="activity-read-more" id="activity-read-more-11938"><a href="https://paragraphfour.com/activity/p/11938/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">c3830ad47787019710fe4d2205854775</guid>
				<title>gregoryglass updated &#039;Court of Appeals Decisions &#8211; by Case Name &#039;: The Paragraph Four Report®
Court of Appeals Opinions by [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11937/</link>
				<pubDate>Fri, 22 May 2026 18:59:03 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>Court of Appeals Opinions by Case Name</b></p>
<p>Opinions from the Court of Appeals for the Federal Circuit can be found in several places in ParagraphFour.com. Each Opinion issued for a particular product can be found under the product name, and you can also see how each individual Appellate Judge ruled in their various&hellip;<span class="activity-read-more" id="activity-read-more-11937"><a href="https://paragraphfour.com/activity/p/11937/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e94e5b01a0875514f3ff9f8984b6b634</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #1 (A-E) &#039;: The Paragraph Four Report ®
Generic Companies Report #1 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11934/</link>
				<pubDate>Thu, 21 May 2026 14:32:48 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #1 (A-E)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11934"><a href="https://paragraphfour.com/activity/p/11934/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a703d416b81d5cee4a55f481350b2721</guid>
				<title>gregoryglass updated &#039;Hetlioz®(tasimelteon) Capsules &#039;: Hetlioz®(tasimelteon) Capsules
Annual Sales  $76.7M [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11933/</link>
				<pubDate>Thu, 21 May 2026 14:29:57 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Hetlioz®(tasimelteon) Capsules</b><br />
<b>Annual Sales </b> $76.7M (product family)<br />
<b>Company </b> VANDA PHARMACEUTICALS<br />
<b>Date of First Filing</b> January 31, 2018</p>
<p><b>Paragraph IV Applicant:</b> Teva<br />
<b>Case Name: </b> VANDA PHARMACEUTICALS INC v. TEVA PHARMACEUTICALS USA INC<br />
<b>Court/Case #: </b> Court of Appeals for the Federal Circuit (cafc) 23-1247<br />
<b>Date Filed:</b> 12/15/22<br />
<b>Judge: </b> Dyk&hellip;<span class="activity-read-more" id="activity-read-more-11933"><a href="https://paragraphfour.com/activity/p/11933/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">43ba5d6be9e8b6aa195784c603a44411</guid>
				<title>gregoryglass updated &#039;Branded Companies Report &#039;: The Paragraph Four Report ®
Branded Companies [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11932/</link>
				<pubDate>Thu, 21 May 2026 13:53:53 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Branded Companies Report</b></p>
<p><b>List of Companies with Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1, 2003)</p>
<p><b>ABBOTT LAB&hellip;</b><span class="activity-read-more" id="activity-read-more-11932"><a href="https://paragraphfour.com/activity/p/11932/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">dc9bfdbdcaa8822fd08777f579a74253</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #1 (A-E) &#039;: The Paragraph Four Report ®
Generic Companies Report #1 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11931/</link>
				<pubDate>Thu, 21 May 2026 13:53:08 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #1 (A-E)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11931"><a href="https://paragraphfour.com/activity/p/11931/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">b3f863120a5788182572119a57b7f671</guid>
				<title>gregoryglass updated &#039;Inter Partes Review List &#039;: The Paragraph Four Report®
Inter Partes Review List

In [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11929/</link>
				<pubDate>Thu, 21 May 2026 13:42:40 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>Inter Partes Review List</b></p>
<p>In late 2012, the Inter Partes Review procedure went into effect allowing anyone to file a Petition with the US Patent and Trademark Office requesting that the USPTO invalidate an issued patent. Over time, this procedure became more common for Paragraph IV products and Orange Book Patents&hellip;<span class="activity-read-more" id="activity-read-more-11929"><a href="https://paragraphfour.com/activity/p/11929/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d7cb3d725a97ba502ea3fa18ecacf35d</guid>
				<title>gregoryglass updated &#039;Paragraph IV Appellate Judges (Prost &#8211; Reyna) &#039;: The Paragraph Four Report®
The Appellate Judges (Prost - [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11928/</link>
				<pubDate>Thu, 14 May 2026 21:27:40 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>The Appellate Judges (Prost &#8211; Reyna)</b></p>
<p>This Section provides data on federal judges who preside in The Federal Circuit Court of Appeals. The Federal Circuit has exclusive appellate jurisdiction over Paragraph IV cases which means that a party that loses in the district court can only appeal the decision to the Federal&hellip;<span class="activity-read-more" id="activity-read-more-11928"><a href="https://paragraphfour.com/activity/p/11928/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">3cbebac8e2bce5e60703657b988ff726</guid>
				<title>gregoryglass updated &#039;Paragraph IV Appellate Judges (Schall &#8211; Wallach) &#039;: The Paragraph Four Report®
The Appellate Judges (Schall - [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11927/</link>
				<pubDate>Thu, 14 May 2026 21:27:03 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>The Appellate Judges (Schall &#8211; Wallach)</b></p>
<p>This Section provides data on federal judges who preside in The Federal Circuit Court of Appeals. The Federal Circuit has exclusive appellate jurisdiction over Paragraph IV cases which means that a party that loses in the district court can only appeal the decision to the&hellip;<span class="activity-read-more" id="activity-read-more-11927"><a href="https://paragraphfour.com/activity/p/11927/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ad90bbe69f2725c46fb5c1f877326239</guid>
				<title>gregoryglass updated &#039;Court of Appeals Decisions &#8211; by Case Name &#039;: The Paragraph Four Report®
Court of Appeals Opinions by [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11926/</link>
				<pubDate>Thu, 14 May 2026 21:24:15 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>Court of Appeals Opinions by Case Name</b></p>
<p>Opinions from the Court of Appeals for the Federal Circuit can be found in several places in ParagraphFour.com. Each Opinion issued for a particular product can be found under the product name, and you can also see how each individual Appellate Judge ruled in their various&hellip;<span class="activity-read-more" id="activity-read-more-11926"><a href="https://paragraphfour.com/activity/p/11926/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">30b37e785fa74f9e8d2a8e3ee67331b3</guid>
				<title>gregoryglass updated &#039;Veletri®(epoprostenol) Injection &#039;: Veletri®(epoprostenol) Injection
Company  ACTELION
Date of [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11925/</link>
				<pubDate>Thu, 14 May 2026 21:17:32 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Veletri®(epoprostenol) Injection</b><br />
<b>Company </b> ACTELION<br />
<b>Date of First Filing</b> March 31, 2017</p>
<p><b>Paragraph IV Applicant:</b> Sun<br />
<b>Case Name: </b> ACTELION PHARMACEUTICALS LTD v. SUN PHARMACEUTICAL INDUSTRIES INC et al<br />
<b>Court/Case #: </b> New Jersey District Court (njdc) 3:2017cv05015<br />
<b>Date Filed:</b> 7/7/17<br />
<b>Judge: </b> Sheridan<br />
<b>Product Strength:</b> 1.5mg/vial and&hellip;<span class="activity-read-more" id="activity-read-more-11925"><a href="https://paragraphfour.com/activity/p/11925/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">cb2c59f58c37d6b7dbe1c4fe6efa6828</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #3 (Q-Z) &#039;: The Paragraph Four Report ®
Generic Companies Report #3 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11923/</link>
				<pubDate>Wed, 13 May 2026 14:01:22 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #3 (Q-Z)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11923"><a href="https://paragraphfour.com/activity/p/11923/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d18243cc4afec7dcbfd97eb241dd4957</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #2 (F-P) &#039;: The Paragraph Four Report ®
Generic Companies Report #2 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11921/</link>
				<pubDate>Fri, 08 May 2026 16:00:20 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #2 (F-P)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11921"><a href="https://paragraphfour.com/activity/p/11921/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d817224142fc58ad990953ec75d48187</guid>
				<title>gregoryglass updated &#039;Xifaxan®(rifaximin) Tablets &#039;: Xifaxan®(rifaximin) Tablets
Company  SALIX
Date of First [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11920/</link>
				<pubDate>Fri, 08 May 2026 15:59:44 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Xifaxan®(rifaximin) Tablets</b><br />
<b>Company </b> SALIX<br />
<b>Date of First Filing</b> December 18, 2015 and January 28, 2019 (200mg)</p>
<p><b>Paragraph IV Applicant:</b> Actavis<br />
<b>Case Name: </b> SALIX PHARMACEUTICALS LTD et al v. ACTAVIS LABORATORIES FL INC<br />
<b>Court/Case #: </b> Delaware District Court (dedc) 1:2016cv00188<br />
<b>Date Filed:</b> 3/23/16<br />
<b>Judge: </b> Sleet<br />
<b>Product Strength:</b> 550&hellip;<span class="activity-read-more" id="activity-read-more-11920"><a href="https://paragraphfour.com/activity/p/11920/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ed1af2bea179aa67054246c9eb8546cf</guid>
				<title>gregoryglass updated &#039;Injectafer®(ferric carboxymaltose) Injection &#039;: Injectafer®(ferric carboxymaltose) Injection 
Company  VIFOR [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11919/</link>
				<pubDate>Tue, 05 May 2026 15:35:56 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Injectafer®(ferric carboxymaltose) Injection </b><br />
<b>Company </b> VIFOR INTERNATIONAL<br />
<b>Date of First Filing</b> March 27, 2019 and February 22, 2024 (50 mg/10 mL)</p>
<p><b>Paragraph IV Applicant:</b> Mylan<br />
<b>Case Name: </b> VIFOR (INTERNATIONAL) AG et al v. MYLAN LABORATORIES LTD<br />
<b>Court/Case #: </b> New Jersey District Court (njdc) 3:2019cv13955<br />
<b>Date Filed:</b> 6/18/19<br />
<b>Judge: </b> Wolfs&hellip;<span class="activity-read-more" id="activity-read-more-11919"><a href="https://paragraphfour.com/activity/p/11919/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">572853b67d4eb25b283d207dac3a0190</guid>
				<title>gregoryglass updated &#039;Invega Sustenna®(paliperidone) ER Inj Suspension &#039;: Invega Sustenna®(paliperidone) Extended-release Injectable [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11917/</link>
				<pubDate>Tue, 05 May 2026 15:08:44 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Invega Sustenna®(paliperidone) Extended-release Injectable Suspension</b><br />
<b>Annual Sales </b> $3.1B (product family)<br />
<b>Company </b> JANSSEN<br />
<b>Date of First Filing</b> November 21, 2017</p>
<p><b>Paragraph IV Applicant:</b> Teva<br />
<b>Case Name: </b> JANSSEN PHARMACEUTICALS INC et al v. TEVA PHARMACEUTICALS USA INC et al<br />
<b>Court/Case #: </b> Court of Appeals for the Federal Circuit (cafc)&hellip;<span class="activity-read-more" id="activity-read-more-11917"><a href="https://paragraphfour.com/activity/p/11917/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">8775a9aefe2e1c120cb56c3efe1ea953</guid>
				<title>gregoryglass updated &#039;Last Month&#8217;s Paragraph IV Highlights &#039;: April 2026</title>
				<link>https://paragraphfour.com/activity/p/11916/</link>
				<pubDate>Fri, 01 May 2026 16:59:31 -0400</pubDate>

									<content:encoded><![CDATA[<p>April 2026</p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">389d7ae4f501e0a875281951f97cffc4</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #2 (F-P) &#039;: The Paragraph Four Report ®
Generic Companies Report #2 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11913/</link>
				<pubDate>Fri, 01 May 2026 16:30:23 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #2 (F-P)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11913"><a href="https://paragraphfour.com/activity/p/11913/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6ada29cb221ce544bee1bbe83e533fce</guid>
				<title>gregoryglass updated &#039;OxyContin®(oxycodone) ER Tabs (NDA 22-272) Part 2 &#039;: OxyContin®(oxycodone) Extended-release Tablet (NDA 22-272) [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11900/</link>
				<pubDate>Fri, 01 May 2026 12:18:03 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>OxyContin®(oxycodone) Extended-release Tablet (NDA 22-272) Part 2</b><br />
<b>Company </b> PURDUE<br />
<b>Date of First Filing</b> October 4, 2010 (40mg), October 18, 2010 (30, 60, and 90mg), October 25, 2010 (10mg), October 28, 2010 (15mg), and October 29, 2010 (20mg).</p>
<p><b>Editor&#8217;s Note</b> This Product Topic covers the fifth set of cases filed on this product since 2001.&hellip;<span class="activity-read-more" id="activity-read-more-11900"><a href="https://paragraphfour.com/activity/p/11900/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6f6ed6ec05737f7fd5b3186e2c51cef1</guid>
				<title>gregoryglass updated &#039;Xarelto®(rivaroxaban) Tablets &#039;: Xarelto®(rivaroxaban) Tablets
Annual Sales  $2.36B (as [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11899/</link>
				<pubDate>Thu, 30 Apr 2026 22:12:48 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Xarelto®(rivaroxaban) Tablets</b><br />
<b>Annual Sales </b> $2.36B (as reported by J&amp;J)<br />
<b>Company </b> BAYER (JANSSEN)<br />
<b>Date of First Filing</b> July 1, 2015 and November 15, 2018 (2.5mg)</p>
<p><b>Special Note 1:</b> On 10/9/15, Bayer filed its PIV case against 7 ANDA filers (Aurobindo through Torrent). Bayer included all three patents against all of the defendants except where&hellip;<span class="activity-read-more" id="activity-read-more-11899"><a href="https://paragraphfour.com/activity/p/11899/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>